CClinicalTrials.gg
Sign In
RecruitingNCT06283862Updated Jun 1, 2026

MIVetsCan: Can-Coach Trial (Phase 2)

An interventional study of Educational Session in Chronic Pain, sponsored by University of Michigan. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by University of Michigan · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
468
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of the MIVetsCan Can-Coach Trial is to test four coaching sessions to help Veterans with chronic pain use their own cannabis products more effectively to manage pain and related symptoms.

Read the detailed description

All study interactions will be done virtually.

02

Conditions studied

  • Chronic Pain

Keywords

  • Veteran
  • Cannabis
  • Cannabidiol
03

In context

Chronic Pain

2,930 studies on the registry are indexed under Chronic Pain; 701 are open to participants now.

This study's planned enrollment of 468 is above the median of 60 across 2,161 interventional studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

University of Michigan is the lead sponsor of 1,475 studies on the registry; 196 are open to participants now.

Of its 162 completed or terminated interventional studies of FDA-regulated products, 128 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • United States Veteran
  • Experiencing chronic pain (pain lasting 3 or more months)
  • Moderate to severe chronic pain
  • Are planning or currently using cannabidiol (CBD) or cannabis products for pain management
  • Able to read and speak English sufficiently to allow for informed consent and active participation in the educational intervention sessions
  • Willingness to attend all study visits (conducted virtually)
  • Willingness to fill out periodic assessments via smartphone to assess symptom status and cannabis use (protocol has more details)

Exclusion criteria

Exclusion Criteria:

  • Inability to provide informed consent (e.g., cognitive impairment, unable to sufficiently communicate in English)
  • Participant states participant is pregnant
  • Planning to move out of a state with legal recreational marijuana use during course of study;
  • Current diagnosis or past history of a psychotic disorder (schizophrenia spectrum, except substance/medication -induced or due to another condition)
  • Current diagnosis or past history of bipolar disorder
  • Unable to attend study visits
  • Risk for imminent harm - Suicidal ideation or wish to die as assessed with the Positive and Negative Suicide Ideation (PANSI) questionnaire and further risk assessment by study team members
  • Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
468 participants (estimated)

Study arms

  • Experimental
    Immediate Education

    Education sessions starting \~ week 4 of trial

    Behavioral: Educational Session

  • Other
    Waitlist Control - delayed education

    Education sessions starting \~ week 12 of trial

    Behavioral: Educational Session

Interventions

  • BehavioralEducational Session

    The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.

06

What researchers measure

Primary outcomes

  1. Patient Global Impression of Change (PGIC) score

    Time frame: Up to 14 weeks

Secondary outcomes

  1. Self-report of pain (intensity or severity) from a numerical rating scale of 0-10

    Self report of pain from a numerical rating scale of 0-10 over 7 day epochs where a higher number score indicates more pain

    Time frame: Up to 14 weeks

  2. Anxiety as measured by the score on the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Profile version 2.1

    Time frame: Up to 14 weeks

  3. Pain interference trends as measured by the score on the PROMIS-29 Profile version 2.1

    Time frame: Up to 14 weeks

  4. Sleep disturbance as measured by the score on the PROMIS-29 Profile version 2.1

    Time frame: Up to 14 weeks

  5. Suicidal ideation as measured by the Positive and Negative Suicide Ideation (PANSI) - Positive ideation

    Time frame: Up to 14 weeks

  6. Suicidal ideation as measured by the Positive and Negative Suicide Ideation (PANSI) - Negative ideation

    Time frame: Up to 14 weeks

07

Study locations

1 of 1 sites recruiting
  • University of Michigan
    Ann Arbor, Michigan 48105, United States
    • Catherine Klida · Contact · CRKlida@umich.edu · 734-998-8010
    • Kevin Boehnke · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06283862
Lead sponsor
University of Michigan
Collaborators
Michigan, State of, Licensing and Regulatory Affairs
Responsible party
Kevin Boehnke (Assistant Professor, Anesthesiology, University of Michigan) — Principal investigator
First posted
Feb 28, 2024
Start date
Apr 4, 2024
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Jun 1, 2026

Study contacts

Catherine Klida
Contact
crklida@umich.edu
734-998-8010
Kevin Boehnke, PhD
study chair · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Chronic Pain→

Other studies from this sponsor

University of Michigan

Start the discussion